# Insights on the Anti-Inflammatory and Anti-Melanogenic Effects of 2′-Hydroxy-2,6′-dimethoxychalcone in RAW 264.7 and B16F10 Cells

**Authors:** Sung-Min Bae, Chang-Gu Hyun

PMC · DOI: 10.3390/cimb47020085 · Current Issues in Molecular Biology · 2025-01-29

## TL;DR

This study shows that 2,6′-dimethoxychalcone effectively reduces inflammation and melanin production in cell models, making it a potential treatment for skin conditions.

## Contribution

The study identifies 2,6′-DMC as a superior chalcone derivative with enhanced anti-inflammatory and anti-melanogenic properties due to its unique structure.

## Key findings

- 2,6′-DMC strongly inhibits NO production and inflammatory markers in RAW 264.7 cells.
- It significantly reduces melanin synthesis in B16F10 cells by downregulating key enzymes and pathways.
- 2,6′-DMC shows minimal skin irritation, indicating safety for topical use.

## Abstract

Chalcones are recognized for their diverse pharmacological properties, including anti-inflammatory and anti-melanogenic effects. However, studies on 2′-hydroxy-2-methoxychalcone derivatives remain limited. This study investigated the anti-inflammatory and melanin synthesis-inhibitory effects of three derivatives: 2′-hydroxy-2,4-dimethoxychalcone (2,4-DMC), 2′-hydroxy-2,5′-dimethoxychalcone (2,5′-DMC), and 2′-hydroxy-2,6′-dimethoxychalcone (2,6′-DMC). In lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages, 2,6′-DMC demonstrated a superior inhibition of nitric oxide (NO) production, pro-inflammatory cytokines, and the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) compared to the other derivatives. A mechanistic analysis revealed that 2,6′-DMC modulates the NF-κB and MAPK signaling pathways to attenuate inflammation. Additionally, 2,6′-DMC exhibited a significant inhibition of α-melanocyte-stimulating hormone (α-MSH)-induced melanin synthesis in B16F10 melanoma cells by downregulating tyrosinase, TRP-1, TRP-2, and MITF expression. This regulation was achieved through the suppression of the Wnt/β-catenin, PI3K/AKT, MAPK, and PKA/CREB pathways. Compared to 2,4-DMC and 2,5′-DMC, 2,6′-DMC’s structural configuration, characterized by methoxy groups at the 2- and 6′-positions, contributed to its enhanced molecular stability and binding affinity, amplifying its inhibitory effects. A primary skin irritation test confirmed that 2,6′-DMC exhibited minimal irritation, demonstrating its safety for dermal applications. These findings suggest that 2,6′-DMC holds promise as a dual-function agent for managing inflammatory conditions and hyperpigmentation-related disorders.

## Linked entities

- **Genes:** NOS2 (nitric oxide synthase 2) [NCBI Gene 4843], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513], LOC103429692 (polyphenol oxidase, chloroplastic-like) [NCBI Gene 103429692], PRSS1 (serine protease 1) [NCBI Gene 5644], DCT (dopachrome tautomerase) [NCBI Gene 1638], MITF (melanocyte inducing transcription factor) [NCBI Gene 4286], MAPK (mitogen activated kinase-like protein) [NCBI Gene 7446652]
- **Chemicals:** 2′-hydroxy-2,4-dimethoxychalcone (PubChem CID 2794957), nitric oxide (PubChem CID 145068)

## Full-text entities

- **Genes:** Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Mitf (melanogenesis associated transcription factor) [NCBI Gene 17342] {aka BCC2, Bhlhe32, Gsfbcc2, Vitiligo, Wh, bw}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, Tyr (tyrosinase) [NCBI Gene 22173] {aka Oca1, albino, c, skc35}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Trp2 (tRNA proline 2) [NCBI Gene 104042] {aka Trp-2}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Tyrp1 (tyrosinase-related protein 1) [NCBI Gene 22178] {aka Oca3, TRP-1, TRP1, Tyrp, b, brown}, Creb1 (cAMP responsive element binding protein 1) [NCBI Gene 12912] {aka 2310001E10Rik, 3526402H21Rik, Creb, Creb-1}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}
- **Diseases:** skin irritation (MESH:D012871), hyperpigmentation-related disorders (MESH:D017495), Inflammatory (MESH:D007249)
- **Cell lines:** B16F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11854153/full.md

## Figures

17 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11854153/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC11854153/full.md

---
Source: https://tomesphere.com/paper/PMC11854153